OncoC4, Inc.
5Patents
5Active
5Granted
41Portfolio score
Filing activity: Sep 19, 2017 → Feb 22, 2022
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11261233B2 | CD80 and CD86 binding protein compositions and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US12129299B2 | Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects | Chemistry; Metallurgy | 0 | Active |
| US11629188B2 | Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12227557B2 | CD80 and CD86 binding protein compositions and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12286485B2 | Anti-CD24 compositions and uses thereof | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.